Develops medicine treatments for cancer patients. Focuses on oral selective Polo-like Kinase 1 (PLK1) Inhibitors for anti-cancer therapeutics. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 13% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 157.3× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 12% of them.
Analysts' average target sits 65% above today's price.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 83% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 13% a year on average.
Sales run at $593K a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 19 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $45.9M against $593K in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 1.3 years. After that, the company needs to find new money.
On our five-subject report card, CRDF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CRDF is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (12/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.